Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURANDOT study of PF-00547659 in moderate to severe ulcerative colitis
NL-OMON38440Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing PF-00547659 dose-ranging arms with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Started Sep 2013; status: active, not recruiting.
02
Drugs
ontamalimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON38440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38440.